PerFem Forte™ - Clinical Trials

I Product Info I Ingredients
I Recommended Use
I Clinical Trials
I Research Brief
I References
perfemlg
 
 
 

Low USA domestic & international

shipping

Indication: menopausal syndrome, hormonal imbalance, cardio-vascular and nervous system support, prevention of osteoporosis and cancer of the female reproductive organs.

Actions: normalizes  the balance of female hormones, relieves symptoms of menopause, antioxidant defense, prevents aging, promotes healthy nervous and  cardiovascular systems, increases endurance and work capacity, has a beneficial impact on appearance.

 

 

Ingredients (per 1 packet):

 

Vitamin E (as d-alpha-tocopheryl succinate) - 15 IU, Thiamin (as thiamin mononitrate) - 1 mg,  Riboflavin - 1 mg, Niacin (as niacinamide) - 10 mg, Vitamin B6 (as pyridoxine HCl) - 3 mg, Folate - 200 mcg, Vitamin B12 (as cyanocobalamin) - 3 mcg, Selenium (as selenium + GMP™) - 35 mcg,  Fermented (aglycone) VDF Isoflavones™ (from organic GMO-Free soybean extract and GMO-Free red clover extract (aerial parts))- 25.5 mg, Black cohosh (Cimicifuga foetida) (12:1) root extract [(8% triterpene glycosides (as 27-deoxyactein)] (equivalent to 150 mg of crude herb) - 12.5 mg.

 

PerFem Forte™ - Clinical Trials:

Modern research has focused on a red clover extract high in isoflavones as a possible treatment for symptoms associated with menopause and cardiovascular health in menopausal women.
In a double-blind study, administration of isoflavones from red clover reduced the frequency of hot flashes in postmenopausal women. The benefit was noticeable after 4 weeks of treatment and became more pronounced after a total of 12 weeks. (10)

Another double-blind trial found that red clover improved cardiovascular function in menopausal women. (11)

In a randomized, double-blind trial, 80 healthy subjects, 46 men and 34 women, 45 to 75 years of age, received isoflavones enriched in either biochanin or formononetin (precursors of genistein and daidzein; 80 mg/d) crossed over randomly with placebo in two 6-week periods. The end points were measured at baseline and after each intervention and included large artery stiffness (systemic arterial compliance and pulse wave velocity), endothelial function in conduit arteries (flow-mediated vasodilation), 24-hour ambulatory blood pressure, and total peripheral resistance. Isoflavone intervention significantly reduced arterial stiffness with improved systemic arterial compliance (P=0.04; repeated-measures ANOVA, Bonferroni correction) attributable to a reduction in total peripheral resistance (P=0.03) and a corresponding reduction in central pulse wave velocity (P=0.02) compared with placebo. Isoflavones did not affect blood pressure (P=0.5) or flow-mediated vasodilation (P=0.44). Improvements seemed limited to formononetin-enriched isoflavones (adjusted P=0.06). Formononetin treatment also reduced circulating vascular adhesion cell molecule-1 (P<0.01).
In normotensive men and postmenopausal women, red clover isoflavones enriched in formononetin reduced arterial stiffness and total vascular resistance but had no effect on blood pressure. These effects may partly explain the lower cardiovascular risk in populations eating isoflavone-rich diets. (12)


At least eight studies of black cohosh therapy for menopausal symptoms, involving approximately 2,000 women, have been published. Almost all of these studies demonstrate efficacy in patients taking black cohosh extract similar to that of estrogen in the treatment of neurovegetative menopausal symptoms.

The study, published in the International Journal of Cancer could offer a new avenue of research for the herb most commonly used by women to reduce menopausal symptoms such as hot flushes.
The researchers used a population-based case-control study consisting of 949 breast cancer cases and 1,524 controls. Demographic information and the use of hormone-related supplements were identified using questionnaires.
After adjusting for potential confounding factors the use of black cohosh was associated with a 61 per cent reduction in the risk of breast cancer, said the researchers. This risk reduction was also observed for Remifemin, a herbal preparation derived from black cohosh, which was calculated to reduce the risk of breast cancer by 53 per cent.
"Substantial additional research must be undertaken before it can be established that black cohosh, or some compound found in black cohosh, is a breast cancer chemopreventive agent," wrote the researchers. "Furthermore, women may wish to seek guidance from their physician before using these compounds," they concluded. (14)